Drugs / CKD-512
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07215637 | Oct 2025 → Mar 2027 expected | metastatic neoplasm, neoplasm | Chong Kun Dang Pharmaceutical | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-27 | Chong Kun Dang Pharmaceutical | Results 종근당, 美 주요 학회서 혁신 파이프라인 연구 성과 발표 ckdpharm.com ↗
종근당은 지난 2일 미국 샌디에이고에서 열린 ‘World ADC 2025’에서 항체-약물 접합체(ADC) 기반 항암 신약 후보물질 ‘CKD-703’의 비임상 연구 결과를 발표했다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-27 | Chong Kun Dang Pharmaceutical | 종근당, 美 주요 학회서 혁신 파이프라인 연구 성과 발표 ckdpharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-512 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07215637 ↗ |
| Route | Oral | “Orally administered BID” NCT07215637 ↗ |